Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Avior Wealth Management LLC

Avior Wealth Management LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 61.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,791 shares of the biopharmaceutical company's stock after selling 7,760 shares during the period. Avior Wealth Management LLC's holdings in Gilead Sciences were worth $490,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bridgewater Associates LP lifted its position in Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after buying an additional 253,994 shares during the period. Nissay Asset Management Corp Japan ADV increased its stake in shares of Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after acquiring an additional 14,009 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its holdings in shares of Gilead Sciences by 54.6% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock worth $3,422,000 after acquiring an additional 13,086 shares during the period. Mufg Securities Americas Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $1,699,000. Finally, JFG Wealth Management LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $427,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 2.1%

GILD traded down $2.31 on Monday, reaching $106.19. The company's stock had a trading volume of 8,170,901 shares, compared to its average volume of 7,663,618. Gilead Sciences, Inc. has a 1 year low of $66.01 and a 1 year high of $119.96. The business's 50 day moving average is $106.16 and its 200 day moving average is $102.88. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The stock has a market cap of $132.09 billion, a price-to-earnings ratio of 22.36, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the company posted ($1.32) EPS. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.98%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the transaction, the insider now directly owns 120,168 shares of the company's stock, valued at $13,238,908.56. This trade represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,500 shares of company stock valued at $5,236,245. Insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Morgan Stanley boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.